Analysis-Innovent’s weight-loss drug highlights China challenge for Novo, Lilly

Innovent Biologics' newly launched weight-loss drug, Xinermei (mazdutide), is rapidly gaining traction in the lucrative Chinese market, posing a significant competitive challenge to Western pharmaceutical giants Novo Nordisk and Eli Lilly. Launched in July, Xinermei is projected to contribute over 600 million yuan this year and reach peak sales of 3.5 billion yuan by 2029, driving Innovent's shares up 155% year-to-date. This local success, bolstered by a strong marketing push, recent approval for Type 2 diabetes, and unique liver health benefits, intensifies pressure on incumbents, particularly as Novo Nordisk faces declining China sales and impending generic competition for its active ingredient semaglutide by 2026-2027.

Analysis

Innovent Biologics is rapidly emerging as a formidable competitor in China's lucrative GLP-1 weight-loss drug market, directly challenging the established positions of Novo Nordisk and Eli Lilly. Since its July launch, Innovent's drug Xinermei (mazdutide) is projected by Morningstar to generate over 600 million yuan in 2025 sales, with peak sales forecast at 3.5 billion yuan by 2029, driving a 155% year-to-date surge in its stock. This momentum is fueled by a savvy marketing strategy, a recent regulatory approval for Type 2 diabetes, and a unique product profile that includes liver fat reduction. In stark contrast, Novo Nordisk's China sales for its competing drug, Wegovy, plummeted from 704 million DKK in Q1 to 158 million DKK in Q2, contributing to a 38% decline in its stock price. Novo's market position is further threatened by the looming 2026 patent expiration of its active ingredient, semaglutide, which will open the door to local generic competition. Eli Lilly faces a more complex situation; while its drug Mounjaro is priced at a premium, Lilly also has an undisclosed financial interest in Innovent's success through a 2019 licensing deal for mazdutide in China.

Key Decisions for Investors

• Given the sharp decline in Novo Nordisk's China sales and the impending 2026 patent cliff for semaglutide, investors should re-evaluate the company's long-term growth and market share assumptions in the region.
• For Eli Lilly, the competitive pressure from Innovent's Xinermei may be partially offset by its licensing agreement, making it critical to monitor any future disclosures on the financial terms of that partnership.
• Innovent's success and 155% stock increase signal a potent 'home-field advantage' for local Chinese biotechs, suggesting investors should monitor other domestic players who could capitalize on the wave of generic GLP-1s expected from 2026.
• The primary risk factor for all incumbents is the timing and pricing of generic semaglutide, so it is prudent to watch for announcements from Chinese regulators and local drugmakers like CSPC Pharmaceutical Group regarding their development pipelines.